

## IN THE SPOTLIGHT

## New Routes to Old Places: *PIK3R1* and *PIK3R2* Join *PIK3CA* and *PTEN* as Endometrial Cancer Genes

Sandra Herrero-Gonzalez and Antonio Di Cristofano

**Summary:** Cheung and colleagues identify *PIK3R1* and *PIK3R2*, the genes encoding the  $\alpha$  and  $\beta$  isoforms of the phosphatidylinositol 3-kinase (PI3K) p85 regulatory subunit, as additional mutation targets in endometrial cancer, and describe a novel mechanism leading to *PTEN* loss. *Cancer Discovery*; 1(2); 106-7. ©2011 AACR.

Commentary on Cheung et al., p. 170(8).

The phosphatidylinositol 3-kinase (PI3K) enzyme is an obligate heterodimer composed of a regulatory subunit (p85) and a catalytic subunit (p110) (1). The inter-SH2 domain of p85 binds to both the adapter-binding domain and the C2 domain of p110, causing its stabilization and catalytic inhibition, respectively (2). Once recruited to the membrane by the interaction of p85 with a variety of receptors, p110 is activated through a conformational switch and produces phosphatidylinositol 3,4,5-trisphosphate (PIP3), which functions as a cellular second messenger. PIP3 recruits kinases containing a pleckstrin homology domain to the cell membrane, where they are activated. These kinases, the most important of which is AKT, control a multitude of pathways, including cell growth, survival, and metabolism (3). The tumor suppressor lipid phosphatase *PTEN* hydrolyzes PIP3 to PIP2, thus acting as a functional antagonist of PI3K (4).

Given the range of biological processes controlled by PI3K, it is not surprising that mutations that lead to aberrant activation of the PI3K cascade are frequent events in human cancers (5). In particular, type I, estrogen-related, endometrial cancer (EC) appears to harbor mutations in PI3K pathway members with a particularly high prevalence (6). Previous reports had established high mutation rates for both *PTEN* and the gene encoding the  $\alpha$  isoform of p110, *PIK3CA* (7). In this issue of *Cancer Discovery*, Cheung and colleagues (8) present an extremely comprehensive analysis of more than 200 primary ECs that validates *PTEN* and *PIK3CA* as primary mutation targets in this tumor type. Interestingly, the data obtained in this study show that, contrary to what had been previously reported in smaller studies, *KRAS* mutations frequently (>10%) coexist with PI3K pathway mutations, suggesting that simultaneous activation of *KRAS* and PI3K cooperates to accelerate the tumorigenic process, similar to what we have recently shown in a thyroid

cancer model (9). This notion, supported by an initial analysis of the correlation between EC genetic alterations and cell line response to mTOR, PI3K, and mitogen-activated protein kinase inhibitors, will now open the way to a more rational combination of targeted therapies in advanced EC patients.

Most importantly, this study also reveals a relatively high rate of mutations in the genes encoding the  $\alpha$  and  $\beta$  isoforms of p85, *PIK3R1* (20%) and *PIK3R2* (5%). The mutation frequency of *PIK3R1* in EC is much higher than previously found in other tumors, and confirms the results of a recent similar analysis performed on a smaller dataset (7). The real novelty is the finding that *PIK3R2* is also frequently mutated in EC, because the mutation rate so far reported in any tumor type was negligible.

Most EC *PTEN* mutations are in heterozygosity, and about half of the *PTEN*<sup>-/-</sup> tumors show complete loss of protein expression, supporting the notion that epigenetic and posttranslational mechanisms contribute to *PTEN* loss during neoplastic transformation. Furthermore, *PTEN* heterozygous mutations frequently coexist with *PIK3CA*, *PIK3R1*, and *PIK3R2* mutations, and in this case a lower percentage of tumors shows complete loss of *PTEN* protein, strongly suggesting that activation of PI3K is necessary and sufficient to overcome the activity of the remaining *PTEN* allele.

These compelling genetic data seem to seriously undermine the notion of *PTEN* haploinsufficiency by providing evidence of mechanisms that bypass the need for total *PTEN* loss to activate PI3K downstream signaling.

A second key finding in the article by Cheung and colleagues (8) comes from the analysis of the effect exerted by *PIK3R1* and *PIK3R2* mutations on PI3K signaling. Based on the current knowledge of p85's role in controlling p110 activation, it is not unexpected that most *PIK3R1* and *PIK3R2* mutations are gain-of-function and work by removing the inhibitory control of p85 over p110; however, one specific *PIK3R1* mutant, E160\*, unexpectedly uncovers a different mechanism that leads to constitutive PI3K activation.

It was previously shown that p85 $\alpha$  interacts with and increases *PTEN* activity (10). Cheung and colleagues (8) now show that expression of wild-type p85 $\alpha$ , but not p85 $\beta$ , increases *PTEN* protein levels through stabilization. Expression of the p85 $\alpha$  E160\* truncation mutant, which cannot bind *PTEN*, leads instead to reduced levels of *PTEN* protein due to increased ubiquitination and degradation. It appears that p85 $\alpha$  binds

**Authors' Affiliation:** Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, New York

**Corresponding Author:** Antonio Di Cristofano, Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Michael F. Price Center for Genetic and Translational Medicine, 1301 Morris Park Avenue, Room 302, Bronx, NY 10461. Phone: 718-678-1137; Fax: 718-678-1020; E-mail: antonio.dicristofano@einstein.yu.edu

doi:10.1158/2159-8290.CD-11-0116

©2011 American Association for Cancer Research.

PTEN as a homodimer, and binding of the mutant p85 $\alpha$  to the wild-type protein impairs the ability of the dimer to interact with and protect PTEN.

Although these data, combined with the finding of *PIK3R1* mutations, may contribute one additional mechanism explaining loss of PTEN protein in *PTEN* wild-type or heterozygous tumors, more stringent validation is now necessary using *in vivo* models to convincingly prove that p85 $\alpha$  protects PTEN from proteasomal degradation in a physiologically relevant system. For example, it would be interesting to reevaluate the data presented by Luo and colleagues (11) showing that loss of one *Pik3r1* allele increases the number of intestinal polyps but decreases prostate cell proliferation, and has no effect on T-cell hyperproliferation in *Pten*<sup>+/-</sup> mice, by comparing the levels of Pten protein in these different tissues showing opposite behavior. Along the same lines, it is important to point out that the levels of Pten protein do not seem to change in the liver of 6-month-old conditional *Pik3r1* mutants (12).

### Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Published online July 18, 2011.

### REFERENCES

1. Vogt PK, Hart JR, Gymnopoulos M, Jiang H, Kang S, Bader AG, et al. Phosphatidylinositol 3-kinase: the oncoprotein. *Curr Top Microbiol Immunol* 2010;347:79-104.
2. Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK. Cancer-derived mutations in the regulatory subunit p85 $\alpha$  of phosphoinositide 3-kinase function through the catalytic subunit p110 $\alpha$ . *Proc Natl Acad Sci U S A* 2010;107:15547-52.
3. Fayard E, Xue G, Parcellier A, Bozulic L, Hemmings BA. Protein kinase B (PKB/Akt), a key mediator of the PI3K signaling pathway. *Curr Top Microbiol Immunol* 2010;346:31-56.
4. Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. *Cell* 2000;100:387-90.
5. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. *Oncogene* 2008;27:5497-510.
6. Di Cristofano A, Ellenson LH. Endometrial carcinoma. *Annu Rev Pathol* 2007;2:57-85.
7. Hayes MP, Wang H, Espinal-Witter R, Douglas W, Solomon GJ, Baker SJ, et al. PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. *Clin Cancer Res* 2006;12:5932-5.
8. Cheung LWT, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, et al. High frequency of *PIK3R1* and *PIK3R2* mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. *Cancer Discovery* 2011;1:170-85.
9. Miller KA, Yeager N, Baker K, Liao XH, Refetoff S, Di Cristofano A. Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells *in vivo*. *Cancer Res* 2009;69:3689-94.
10. Chagpar RB, Links PH, Pastor MC, Furber LA, Hawrysh AD, Chamberlain MD, et al. Direct positive regulation of PTEN by the p85 subunit of phosphatidylinositol 3-kinase. *Proc Natl Acad Sci U S A* 2010;107:5471-6.
11. Luo J, Sobkiw CL, Logsdon NM, Watt JM, Signoretti S, O'Connell F, et al. Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN<sup>+/-</sup> mice by the p85 regulatory subunits of phosphoinositide 3-kinase. *Proc Natl Acad Sci U S A* 2005;102:10238-43.
12. Taniguchi CM, Winnay J, Kondo T, Bronson RT, Guimaraes AR, Aleman JO, et al. The phosphoinositide 3-kinase regulatory subunit p85 $\alpha$  can exert tumor suppressor properties through negative regulation of growth factor signaling. *Cancer Res* 2010;70:5305-15.

# CANCER DISCOVERY

## New Routes to Old Places: *PIK3R1* and *PIK3R2* Join *PIK3CA* and *PTEN* as Endometrial Cancer Genes

Sandra Herrero-Gonzalez and Antonio Di Cristofano

*Cancer Discovery* 2011;1:106-107.

**Updated version** Access the most recent version of this article at:  
<http://cancerdiscovery.aacrjournals.org/content/1/2/106>

**Cited articles** This article cites 12 articles, 7 of which you can access for free at:  
<http://cancerdiscovery.aacrjournals.org/content/1/2/106.full#ref-list-1>

**Citing articles** This article has been cited by 2 HighWire-hosted articles. Access the articles at:  
<http://cancerdiscovery.aacrjournals.org/content/1/2/106.full#related-urls>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link  
<http://cancerdiscovery.aacrjournals.org/content/1/2/106>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.